Eunice Wang, MD

Menin inhibitors such as ziftomenib and revumenib target NPM1 and KMT2A AML, pushing precision therapy earlier with manageable toxicity.

Learn how NPM1 MRD qPCR predicts relapse, shapes transplant decisions, and emerging trials test MRD negativity as a treatment target in AML.

Triplet therapy with ziftomenib, venetoclax, and azacitidine boosts responses in venetoclax‑naive NPM1‑mutated AML; phase 3 trials test frontline benefit.

KOMET-007 shows ziftomenib plus venetoclax/azacitidine drives deep MRD-negative remissions in R/R AML, with manageable toxicity and longer responses.

KOMET-007 tests ziftomenib with venetoclax and azacitidine in relapsed/refractory AML, selecting 600 mg to boost responses and guide future menin-based regimens.

Triplet therapy ziftomenib plus venetoclax/azacitidine boosts MRD-negative remissions in relapsed NPM1-mutated AML, hinting at earlier use.

Eunice S. Wang, MD, discusses a retrospective study of 105 patients diagnosed with secondary acute myeloid leukemia.

Eunice S. Wang, MD, discusses the role of transplant eligibility in shaping treatment strategies for secondary acute myeloid leukemia.

Eunice S. Wang, MD, discusses research behind optimal therapy for acute myeloid leukemia secondary to other malignancies, particularly in patients with prior myelodysplastic syndrome.

FLT3 tyrosine kinase inhibitor combination regimens may hold promise to not only improve outcomes for older individuals with FLT3-mutant but potentially for all patients , regardless of age or fitness.

Eunice Wang, MD, discusses the excitement she has experienced in the treatment landscape of acute myeloid leukemia over the last several years due to the number of new treatment options approved by the FDA.

Eunice Wang, MD, discusses the new treatment era for patients with acute myeloid leukemia after the approval of 3 new treatment regimens at the end of 2018.

Eunice Wang, MD, discusses an ongoing phase III trial looking at vincristine sulfate liposomes injection (Marqibo) for the treatment of patients ≥ 60 years old with newly diagnosed acute lymphoblastic leukemia (ALL).